掺钬(III)多功能纳米诊疗剂用于超高场磁共振成像引导的化疗-光热肿瘤治疗。

Holmium (III)-doped multifunctional nanotheranostic agent for ultra-high-field magnetic resonance imaging-guided chemo-photothermal tumor therapy.

机构信息

School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.

Shenzhen International Institute for Biomedical Research, Silver Star Hi-tech Park, Longhua District, Shenzhen, Guangdong, 518116, China.

出版信息

Acta Biomater. 2023 Dec;172:454-465. doi: 10.1016/j.actbio.2023.10.017. Epub 2023 Oct 18.

Abstract

Ultra-high-field (UHF) MRI has shown great advantages over low-field magnetic resonance imaging (MRI). Despite being the most commonly used MRI contrast agents, gadolinium chelates perform poorly in high magnetic fields, which significantly weakens their T intensity. In comparison, the rare element Holmium (Ho)-based nanoparticles (NPs) have demonstrated great potential as T-weighted MRI contrast agents in UHF MRI due to their extremely short electron relaxation times (∼ 10s). In this study, a multifunctional nanotherapeutic probe was designed for UHF MRI-guided chemotherapy and photothermal therapy. The Ho (III)-doped mesoporous polydopamine (Ho-MPDA, HM) nanosphere was loaded with the chemotherapeutic drug mitoxantrone (MTO) and then coated with 4T1 cell membranes to enhance active targeting delivery to breast cancer. The prepared nanotherapeutic probe MTO@HMM@4T1 (HMM@T) exhibited good biocompatibility, high drug-loading capability and great potential as Ho (III)-based UHF MRI contrast agents. Moreover, the biodegradation of HMM@T in response to the intratumor pH and glutathione (GSH) promotes MTO release. Near-infrared (NIR) light irradiation of HM induced photothermal therapy and further enhanced drug release. Consequently, HMM@T effectively acted as an MRI-guided tumor-targeting chemo-photothermal therapy against 4T1 breast cancer. STATEMENT OF SIGNIFICANCE: Ultra-high-field (UHF) MRI has shown great advantages over low-field magnetic resonance imaging (MRI). Although gadolinium chelates are the most commonly used MRI contrast agents in clinical practice, they exhibit a significantly decreased T relaxivity at UHF. Holmium exhibits outstanding UHF magnetic resonance capabilities in comparison with gadolinium chelates currently used in clinic. Herein, a theranostic nanodrug (HMM@T) was designed for UHF MRI-guided chemo-photothermal therapy. The nanodrug possessed remarkable UHF T MRI properties (r = 152.13 mMs) and high drug loading capability of 18.4 %. The biodegradation of HMM@T NPs under triple stimulations of pH, GSH, and NIR led to an efficient release of MTO in tumor microenvironment. Our results revealed the potential of a novel UHF MRI-guided multifunctional nanosystem in cancer treatment.

摘要

超高场 (UHF) MRI 比低场磁共振成像 (MRI) 具有很大的优势。尽管镧系螯合物是临床实践中最常用的 MRI 对比剂,但它们在 UHF 下的 T 弛豫率显著降低。与目前临床使用的镧系螯合物相比,钬表现出优异的 UHF 磁共振性能。在此,设计了一种用于 UHF MRI 引导化疗和光热治疗的治疗诊断纳米药物 (HMM@T)。Ho(III)掺杂介孔聚多巴胺 (Ho-MPDA,HM) 纳米球负载化疗药物米托蒽醌 (MTO),然后包覆 4T1 细胞膜,以增强对乳腺癌的主动靶向递药。所制备的纳米药物 MTO@HMM@4T1 (HMM@T) 表现出良好的生物相容性、高载药能力和作为基于 Ho(III)的 UHF MRI 对比剂的巨大潜力。此外,HMM@T 在肿瘤微环境中响应 pH 和谷胱甘肽 (GSH) 的生物降解促进 MTO 释放。HM 的近红外 (NIR) 光照射诱导光热治疗并进一步增强药物释放。因此,HMM@T 有效地作为一种 MRI 引导的针对 4T1 乳腺癌的肿瘤靶向化疗-光热治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索